Compare WHG & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | TTRX |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 174.9M |
| IPO Year | 2002 | N/A |
| Metric | WHG | TTRX |
|---|---|---|
| Price | $20.34 | $9.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 31.4K | ★ 64.4K |
| Earning Date | 04-30-2026 | 05-31-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $97,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $226.00 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.70 | $2.57 |
| 52 Week High | $20.97 | $9.77 |
| Indicator | WHG | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 73.89 |
| Support Level | $15.78 | $4.40 |
| Resistance Level | $20.97 | N/A |
| Average True Range (ATR) | 1.17 | 0.89 |
| MACD | 0.08 | 0.25 |
| Stochastic Oscillator | 70.76 | 58.77 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.